LivaNova (LIVN) Cash from Investing Activities Growth (1y) (2017 - 2026)
LivaNova (LIVN) Cash from Investing Activities Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -4,224.26% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 95.53% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -18.20% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -208.79% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -397.90% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -514.25% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -187.82% |
| 10 | LivaNova | 4.40 Bn | 3.86 Bn | 243.75 Mn | -37.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.18% |
| Dec 31, 2025 | -182.58% |
| Sep 30, 2025 | -24.50% |
| Jun 30, 2025 | 28.65% |
| Mar 31, 2025 | -67.03% |
| Dec 31, 2024 | 11.78% |
| Sep 30, 2024 | -84.21% |
| Jun 30, 2024 | -88.87% |
| Mar 31, 2024 | 44.59% |
| Dec 31, 2023 | -10.82% |
| Sep 30, 2023 | -72.42% |
| Jun 30, 2023 | 58.79% |
| Mar 31, 2023 | -109.49% |
| Dec 31, 2022 | -201.65% |
| Sep 30, 2022 | 5.65% |
| Jun 30, 2022 | -128.54% |
| Mar 31, 2022 | 44.39% |
| Dec 31, 2021 | 57.32% |
| Sep 30, 2021 | 42.09% |
| Jun 30, 2021 | 588.50% |